表紙
市場調査レポート

Gタンパク質共役受容体(GPCR)標的:技術・世界市場

G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets

発行 BCC Research 商品コード 310059
出版日 ページ情報 英文 508 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.71円で換算しております。
Back to Top
Gタンパク質共役受容体(GPCR)標的:技術・世界市場 G-Protein Coupled Receptor (GPCR) Targeting: Technologies and Global Markets
出版日: 2014年08月08日 ページ情報: 英文 508 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界のGタンパク質共役受容体(GPCR)標的薬市場は、一連のベストセラー薬剤の特許期限切れにより、過去3年間で急激に落ち込みました。同市場は2010-2013年間にマイナス3.4%のCAGRを示し、市場額は1,110億米ドルから約1,000億米ドルへと減少しました。新薬の投入および新たに登場する薬剤クラスにより、市場は2013-2018年間に2.7%のCAGRで拡大し、2018年までに1,140億米ドルに達すると予測されています。

当レポートでは、世界のGタンパク質共役受容体(GPCR)標的および関連技術市場について調査し、市場概要、市場動向の分析、地域別の市場分析、関連特許の分析、および主要企業のプロファイルなどをまとめ、お届けいたします。

第1章 イントロダクション

第2章 サマリー

第3章 概要

  • Gタンパク質共役受容体(GPCR)
  • GPCRはどのように細胞応答を誘発するか?
  • 病理生理学におけるGPCRの重要性
  • GPCR標的
  • GPCR標的薬の分類

第4章 規制状況

第5章 世界市場

  • 市場分析
  • ロドプシン様受容体治療薬
  • セクレチン様受容体治療薬
  • 代謝型グルタミン酸/フェロモン受容体治療薬
  • 市場分析:治療用途別
  • 中枢神経系(CNS)治療薬
  • 呼吸器治療薬
  • 免疫系
  • 内分泌/代謝治療薬
  • がん治療薬
  • 泌尿生殖器治療薬
  • 眼科

第6章 米国市場

  • 市場分析
  • ロドプシン様受容体治療薬
  • セクレチン受容体治療薬
  • 代謝型グルタミン酸治療薬
  • 市場分析:治療用途別
  • 中枢神経系(CNS)治療薬
  • 呼吸器治療薬
  • 免疫系治療薬
  • 内分泌/代謝治療薬
  • がん治療薬
  • 泌尿生殖器治療薬
  • 眼科

第7章 EU市場

第8章 日本市場

第9章 BRIC市場

第10章 世界のその他の市場

第11章 企業プロファイル

図表リスト

目次
Product Code: BIO136A

REPORT HIGHLIGHTS

The global G protein, coupled receptors (GPCR) targeting drug market sharply fell in the last three years due to a series of patent expirations of blockbuster products. The market receded from nearly $111 billion to almost $100 billion with a -3.4% compound annual growth rate (CAGR) between 2010 and 2013. With the introduction of novel pharmacecuticals and newly appearing classes of drugs, BCC Research expects this market to reach $114 billion by 2018, a CAGR of 2.7% from 2013 to 2018.

This report provides:

  • An overview of the global market for G-protein coupled ceceptor (GPCR) targeting and related technologies.
  • Analyses of global market trends, with data from 2010, 2011, 2012, 2013 and projections of compound annual growth rates (CAGRs) through 2018.
  • A breakdown of the market into the regions the U.S; Europe; Japan; Brazil, Russia, India, China (BRIC), and the rest of the world.
  • Relevant patent anlaysis.
  • Comprehensive profiles of major companies in the industry.

SCOPE OF THE STUDY

The scope of this study encompasses the GPCR targeting drugs in pharmaceutical and biopharmaceutical markets. BCC Research analyzed each market and its applications, regulatory environment, technology, market projections and market share. Technological issues include the latest trends and developments. The strong growing market for the GPCR drugs includes the countries of the EU such as the U.K., France, Germany, Spain and Italy, and also include the emerging countries such as China, Brazil, South Korea, Taiwan, Mexico and other countries.

ANALYST'S CREDENTIALS

This report was authored by Ufuk Ezer. Ezer holds a bachelor's degree in bioengineering and a master's degree in biotechnology, bioprocessing and business management. The analyst possesses extensive pharmaceutical research and development experience through participating projects in various international institutions and organizations. Ezer has been granted scholarships and awards during his post-study works in countries such as Japan and Panama due to his high quality of work and excellence in the fields of research.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY OBJECTIVES
  • REASONS FOR DOING THE STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)

CHAPTER 3 - OVERVIEW

  • G PROTEIN-COUPLED RECEPTORS
  • HOW DO GPCRS INDUCE CELLULAR RESPONSES?
  • IMPORTANCE OF GPCRS IN DISEASE PHYSIOLOGY
  • GPCR TARGETING
  • CLASSIFICATION OF GPCR-TARGETING DRUGS
    • CLASS-A: RHODOPSIN-LIKE RECEPTOR TARGETING DRUGS
      • Peptide Receptor Drugs
      • Biogenic Amine Receptor Drugs
      • Hormone Receptor Drugs
      • Lipid-derived Ligand (Lipid and Phospholipid) Receptor Drugs
      • Nucleotide Receptor Drugs
    • CLASS B: SECRETIN RECEPTORS
      • Peptide Receptor Drugs
      • Hormone Receptor Drugs
      • CLASS C: METABOTROPIC GLUTAMATE RECEPTOR DRUGS
      • Proteinogenic Amino Acid Receptor Drugs
      • Ion Receptor Drugs
        • TABLE 1: CLASSIFICATION OF THE GPCR-TARGETING DRUGS

CHAPTER 4 - REGULATORY ASPECTS

  • TABLE 2: FDA-APPROVED GPCR TARGETING DRUGS, 2010-2014
  • TABLE 3: POSITIVE OPINION GRANTED BY THE EMA TO GPCR TARGETING DRUGS, 2012-2014
  • TABLE 4: BOX WARNINGS ENFORCED BY THE FDA FOR THE USE OF SELECTED GPCR-TARGETING DRUGS

CHAPTER 5 - GLOBAL MARKETS

  • MARKET ANALYSIS
    • TABLE 5: GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
  • RHODOPSIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Angiotensin II Receptor Antagonists
        • Major Products
        • Angiotensin II Receptor Targeting Drugs in Development
          • TABLE 6: ARB'S IN DEVELOPMENT, BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 7: GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
          • FIGURE 2: GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
      • Bradykinin Receptor Antagonists
        • Major Product
        • Market Revenue
          • TABLE 8: GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 3: GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Opioid Receptor Targeting Drugs
        • Major Products (Opioids)
        • Major Products (Opioid Antagonists)
        • Opioids in Development
          • TABLE 9: OPIOIDS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 10: GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 4: GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Chemokine Receptor Antagonists
        • Major Products
        • Chemokine Receptor Antagonists in Development
          • TABLE 11: CHEMOKINE RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 12: GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 5: GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Somatostatin Receptor Agonists
        • Major Products
        • Sandostatin Receptor Agonists in Development
          • TABLE 13: SOMATOSTATIN RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 14: GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 6: GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
      • Neurokinin Receptor Antagonists
        • Major Products
        • Market Revenue
          • TABLE 15: GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 7: GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Vasopressin Receptor Antagonists
        • Major Products
        • Vasopressin Antagonists in Development
        • Market Revenue
          • TABLE 16 GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 8 GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Endothelin Receptor Antagonists
        • Major Products
        • ERAs in Development
        • Market Revenue
          • TABLE 17: GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 9: GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • New Drug Classes in A-peptide Sub-class
        • Orexin Receptor Antagonists
        • Relaxin Receptor Agonists
    • Biogenic Amine Receptor Drugs
      • Muscarinic Receptor Targeting Drugs
        • Muscarinic Receptor Agonists
        • Muscarinic Agonists in Development
        • Muscarinic Receptor Antagonists
          • Major Products
          • Other Products
        • Muscarinic Receptor Antagonists in Development
        • Market Revenue
          • TABLE 18: GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 10: GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Adrenergic Receptor Targeting Drugs
      • Alpha-Adrenergic Receptor Agonists
      • Alpha-Adrenergic Receptor Antagonists
        • Major Products
      • Beta-Adrenergic Receptor Agonists
        • Major Products
      • Beta-Adrenergic Receptor Antagonists
        • Major Products
    • Adrenergic Receptor Targeting Drugs in Development
      • Market Revenue
        • TABLE 19: GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 11: GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Dopamine Receptor Targeting Drugs
      • Dopamine Receptor Agonists
        • Major Products
      • Dopamine Receptor Antagonists and Inverse Agonists
        • Major Products
      • Dopamine Receptor Targeting Drugs in Development
        • Market Revenue
          • TABLE 20: GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 12: GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Histamine Receptor Antagonists
      • Major Products
      • Market Revenue
        • TABLE 21: GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 13: GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Serotonin Receptor Targeting Drugs
      • Serotonin Receptor Agonists
        • Major Products
      • Serotonin Receptor Agonists in Development
      • Serotonin Receptor Antagonists
        • Major Products
      • Serotonin Receptor Antagonists in Development
        • TABLE 22: SEROTONIN RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
      • Market Revenue
        • TABLE 23: GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 14: GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • Follicle Stimulating Hormone (FSH) Receptor Agonists
        • Major Products
      • Luteinizing Hormone (LH) Receptor Agonists
        • Major Product
      • Gonadotropin Releasing Hormone (GnRH) Receptor Agonists
        • Major Products
        • Market Revenue
          • TABLE 24: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 15: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Lipid and Phospholipid Receptor Drugs
      • Eicosanoid Receptor Agonists
        • Major Product (Prostaglandins)
        • Major Products (Leukotriene)
        • Prostaglandin and Prostacyclin Receptor Agonists in Development
          • TABLE 25: EICOSANOID RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 26: GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 16: GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • S1P Receptor Modulators
        • Major Product
        • S1P Receptor Modulators in Development
          • TABLE 27: S1P RECEPTOR MODULATORS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 28 GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 17: GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Nucleotide Receptor Drugs
      • P2Y Receptor Antagonists
        • Major Products
        • Market Revenue
          • TABLE 29: GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 18: GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
  • SECRETIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Amylin Receptor Agonists
        • Major Product
        • Market Revenue
          • TABLE 30: GLOBAL MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 19: GLOBAL MARKET FOR AMYLIN RECEPTOR AGONIST, 2010-2018 ($ MILLIONS)
      • Glucagon-like Peptide (GLP) Receptor Agonists
        • Major Products
        • Other Products
        • GLPR Agonists in Development
          • TABLE 31: GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
        • Market Revenue
          • TABLE 32: GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 20: GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
      • Smoothened (SMO) Receptor Antagonists
        • Major Product
        • SMO Receptor Antagonists in Development
        • Market Revenue
          • TABLE 33: GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 21: GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • New Drug Classes in B-peptide Sub-class
        • Calcitonin Gene-related Peptide (CGRP) Receptor Antagonists
        • Frizzled Receptor Blockers
    • Hormone Receptor Drugs
      • Parathyroid Hormone (PTH) Receptor Agonists
        • Major Product
        • Other Product
        • Market Revenue
          • TABLE 34: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 22: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
  • METABOTROPIC GLUTAMATE/PHEROMONE RECEPTOR DRUGS
    • Proteinogenic Amino Acid Receptor Drugs
      • Metabotropic Glutamate Receptor Targeting Drugs
        • mGuR-targeting Drugs in Development
    • Ion Receptor Drugs
      • Calcium-sensing Receptor (CaSR) Agonists
        • Major Products
        • CaSR Agonists in Development
        • Market Revenue
          • TABLE 35: GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 23: GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
  • MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    • CARDIOVASCULAR DRUGS
      • FIGURE 24: GLOBAL MARKET SHARE FOR GPCR CARDIOVASCULAR DRUGS, 2013 (%)
      • TABLE 36: GLOBAL MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 25: GLOBAL MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
      • FIGURE 26: REGIONAL MARKETS FOR GPCR CARDIOVASCULAR DRUGS, 2010-2018 ($ MILLIONS)
      • Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 27: GLOBAL MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
      • Platelet Aggregation Inhibitors
        • Overview
        • Revenue
          • FIGURE 28: GLOBAL MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
      • Other Anti-hypertensives
        • Overview
        • Revenue
          • FIGURE 29: GLOBAL MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
  • CENTRAL NERVOUS SYSTEM (CNS) DRUGS
    • FIGURE 30: GLOBAL MARKET SHARE FOR GPCR CNS DRUGS, 2013 (%)
    • TABLE 37: GLOBAL MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 31: GLOBAL MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)
    • FIGURE 32: REGIONAL MARKETS FOR GPCR CNS DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Psychotics
      • Overview
      • Revenue
        • FIGURE 33: GLOBAL MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • Anti-Depressants
      • Overview
      • Revenue
        • FIGURE 34: GLOBAL MARKET FOR GPCR ANTI-DEPPRESSANT DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Parkinson's Drugs
      • Overview
      • Revenue
        • FIGURE 35: GLOBAL MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Migraine Drugs
      • Overview
      • Revenue
        • FIGURE 36: GLOBAL MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 ($ MILLIONS)
    • Nootropics
      • Overview
      • Revenue
        • FIGURE 37: GLOBAL MARKET FOR GPCR NOOTROPIC DRUGS, 2010-2018 ($ MILLIONS)
    • Psychostimulants
      • Overview
      • Revenue
        • FIGURE 38: GLOBAL MARKET FOR GPCR PSYCHOSTIMULANT DRUGS, 2010-2018 ($ MILLIONS)
    • Analgesics
      • Overview
      • Revenue
        • FIGURE 39: GLOBAL MARKET FOR GPCR ANALGESIC DRUGS, 2010-2018 ($ MILLIONS)
    • Opioid Dependence Medications
      • Overview
      • Revenue
        • FIGURE 40: GLOBAL MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
  • RESPIRATORY DRUGS
    • FIGURE 41: GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUGS, 2013 (%)
    • TABLE 38: GLOBAL MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 42: GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)
    • FIGURE 43: REGIONAL MARKETS FOR GPCR RESPIRATORY DRUGS, 2010-2018 ($ MILLIONS)
    • Bronchodilators and Anti-Inflammatories
      • Overview
      • Revenue
        • FIGURE 44: GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 ($ MILLIONS)
    • Anti-Allergics
      • Overview
      • Revenue
        • FIGURE 45: GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 ($ MILLIONS)
  • IMMUNE SYSTEM
    • FIGURE 46: GLOBAL MARKET SHARE FOR GPCR IMMUNOLOGY DRUGS, 2013
    • TABLE 39: GLOBAL MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 47: GLOBAL MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)
    • FIGURE 48: REGIONAL MARKETS FOR THE GPCR IMMUNOLOGY DRUGS, 2010-2018 ($ MILLIONS)
    • Immunosuppressants
      • Overview
      • Revenue
        • FIGURE 49: GLOBAL MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Retrovirals
      • Overview
      • Revenue
        • FIGURE 50: GLOBAL MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
  • ENDOCRINOLOGY/METABOLIC DRUGS
    • FIGURE 51: GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2013 (%)
    • TABLE 40: GLOBAL MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 52: GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUG COMPANIES, 2013 (%)
    • FIGURE 53: REGIONAL MARKETS FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Diabetics
      • Overview
      • Revenue
        • FIGURE 54: GLOBAL MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • Infertility Treatments
      • Overview
      • Revenue
        • FIGURE 55: GLOBAL MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • Hormone Therapies
      • Overview
      • Revenue
        • FIGURE 56: GLOBAL MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
  • ONCOLOGY DRUGS
    • FIGURE 57 GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUGS, 2013
    • TABLE 41: GLOBAL MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 58: GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 ($ MILLIONS)
    • FIGURE 59: REGIONAL MARKET FOR GPCR ONCOLOGY DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Neoplastic Drugs
      • Overview
      • Revenue
        • FIGURE 60: GLOBAL MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • Anti-Emetics
      • Overview
      • Revenue
        • FIGURE 61: GLOBAL MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • Hematopoietic Stem Cell Mobilizers (HSCMs)
      • Overview
      • Revenue
        • FIGURE 62: GLOBAL MARKET FOR GPCR HEMATOPOIETIC STEM CELL MOBILIZERS, 2010-2018 ($ MILLIONS)
  • GENITOURINARY DRUGS
    • FIGURE 63: GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUGS, 2013 (%)
    • TABLE 42: GLOBAL MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 64: GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)
    • FIGURE 65: REGIONAL MARKET FOR GPCR GENITOURINARY DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Diuretics
      • Overview
      • Revenue
        • FIGURE 66: GLOBAL MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • Diuretics
      • Overview
      • Revenue
        • FIGURE 67: GLOBAL MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
  • OPHTHALMICS
    • TABLE 43: GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 68: GLOBAL MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)
    • FIGURE 69: REGIONAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Glaucoma Drugs
      • Overview
      • Revenue
        • FIGURE 70: GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)

CHAPTER 6 - MARKETS IN THE UNITED STATES

  • MARKET ANALYSIS
    • TABLE 44: U.S. MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 71: U.S. MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
  • RHODOPSIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Angiotensin II Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 45: U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
          • FIGURE 72: U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
      • Bradykinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 46: U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 73: U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Opioid Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 47: U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 74: U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Chemokine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 48: U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 75 U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Somatostatin Receptor Agonists
        • Overview
        • Revenue
          • TABLE 49: U.S. MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 76: U.S. MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
      • Neurokinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 50: U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 77: U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Vasopressin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 51: U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 78: U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Endothelin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 52: U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 79: U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Biogenic Amine Receptor Drugs
      • Muscarinic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 53 U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 80 U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Adrenergic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 54: U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 81: U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Dopamine Receptor Drugs
        • Overview
        • Revenue
          • TABLE 55: U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 82: U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Histamine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 56: U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 83: U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Serotonin Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 57: U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 84: U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • FSH, LH and GNRH Receptor Drugs
        • Overview
        • Revenue
          • TABLE 58: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 85: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Lipid and Phospholipid Receptor Drugs
      • Eicosanoid Receptor Drugs
        • Overview
        • Revenue
          • TABLE 59: U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 86: U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • S1P Receptor Modulators
        • Overview
        • Revenue
          • TABLE 60: U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 87: U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Nucleotide Receptor Drugs
      • P2Y Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 61: U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 88: U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
  • SECRETIN RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Amylin Receptor Agonists
        • Overview
        • Revenue
          • TABLE 62: U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 89: U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
      • Glucagon-like Peptide (GLP) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 63: U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 90: U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
      • Smoothened (SMO) Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 64: U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 91: U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • Parathyroid Hormone (PTH) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 65: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 92: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
  • METABOTROPIC GLUTAMATE RECEPTOR DRUGS
    • Calcium-sensing Receptor (CaSR) Agonists
      • Overview
      • Revenue
        • TABLE 66: U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
        • FIGURE 93: U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
  • MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    • CARDIOVASCULAR DRUGS
      • TABLE 67: U.S. MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 94: U.S. MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
      • Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 95: U.S. MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
      • Platelet Aggregation Inhibitors
        • Overview
        • Revenue
          • FIGURE 96: U.S. MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
      • Other Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 97: U.S. MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
  • CENTRAL NERVOUS SYSTEM (CNS) DRUGS
    • TABLE 68: U.S. MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 98: U.S. MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013
    • Anti-Psychotics
      • Overview
      • Revenue
        • FIGURE 99: U.S. MARKET FOR GPCR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • Anti-Depressants
      • Overview
      • Revenue
        • FIGURE 100: U.S. MARKET FOR GPCR ANTI-DEPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Parkinson's Drugs
      • Overview
      • Revenue
        • FIGURE 101: U.S. MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 ($ MILLIONS)
    • Anti-Migraine Drugs
      • Overview
      • Revenue
        • FIGURE 102: U.S. MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 ($ MILLIONS)
    • Nootropics
      • Overview
      • Revenue
        • FIGURE 103: U.S. MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • Psychostimulants
      • Overview
      • Revenue
        • FIGURE 104: U.S. MARKET FOR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • Analgesics
      • Overview
      • Revenue
        • FIGURE 105: U.S. MARKET FOR ANALGESICS, 2010-2018 ($ MILLIONS)
    • Opioid Dependence Medications
      • Overview
      • Revenue
        • FIGURE 106: U.S. MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
  • RESPIRATORY DRUGS
    • TABLE 69: U.S. MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 107: U.S. MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)
    • Bronchodilators and Anti-Inflammatories
      • Overview
      • Revenue
        • FIGURE 108: U.S. MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • Anti-Allergics
      • Overview
      • Revenue
        • FIGURE 109: U.S. MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
  • IMMUNOLOGY DRUGS
    • TABLE 70: U.S. MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 110: U.S. MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)
    • Immunosuppressants
      • Overview
      • Revenue
        • FIGURE 111: U.S. MARKET FOR GPCR IMMUNOSUPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Retrovirals
      • Overview
      • Revenue
        • FIGURE 112: U.S. MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
  • ENDOCRINOLOGY/METABOLIC DRUGS
    • TABLE 71: U.S. MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 113: U.S. MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • Anti-Diabetics
      • Overview
      • Revenue
        • FIGURE 114: U.S. MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • Infertility Treatments
      • Overview
      • Revenue
        • FIGURE 115: U.S. MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • Hormone Therapies
      • Overview
      • Revenue
        • FIGURE 116: U.S. MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
  • ONCOLOGY DRUGS
    • TABLE 72: U.S. MARKET FOR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 117: U.S. MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, THROUGH 2018 (%)
    • Anti-Neoplastic Agents
      • Overview
      • Revenue
        • FIGURE 118: U.S. MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • Anti-Emetics
      • Overview
      • Revenue
        • FIGURE 119: U.S. MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • Hematopoietic Stem Cell Mobilizers (HSCMs)
      • Overview
      • Revenue
        • FIGURE 120: U.S. MARKET FOR GPCR HSCMS, 2010-2018 ($ MILLIONS)
  • GENITOURINARY DRUGS
    • TABLE 73: U.S. MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 121: U.S. MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)
    • Anti-Diuretics
      • Overview
      • Revenue
        • FIGURE 122: U.S. MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • Diuretics
      • Overview
      • Revenue
        • FIGURE 123: U.S. MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
  • OPHTHALMIC DRUGS
    • Anti-Glaucoma Drugs
      • Overview
      • Revenue
        • TABLE 74: U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 124: U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
        • FIGURE 125: U.S. MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)

CHAPTER 7 - MARKETS IN THE EUROPEAN UNION

  • MARKET ANALYSIS
    • TABLE 75: EU MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 126: EU MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
  • RHODOPSIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Angiotensin II Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 76: EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
          • FIGURE 127: EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
      • Bradykinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 77: EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 128: EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Opioid Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 78: EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 129: EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Chemokine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 79: EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 130: EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Somatostatin Receptor Agonists
        • Overview
        • Revenue
          • TABLE 80: EU MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 131: EU MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
      • Neurokinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 81: EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 132: EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Vasopressin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 82: EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 133: EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Endothelin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 83: EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 134: EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Biogenic Amine Receptor Drugs
      • Muscarinic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 84: EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 135: EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Adrenergic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 85: EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 136: EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Dopamine Receptor Drugs
        • Overview
        • Revenue
          • TABLE 86: EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 137: EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Histamine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 87: EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 138: EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Serotonin Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 88: EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 139: EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • FSH, LH AND GNRH Receptor Drugs
        • Overview
        • Revenue
          • TABLE 89: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 140: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Lipid and Phospholipid Receptor Drugs
      • Eicosanoid Receptor Drugs
        • Overview
        • Revenue
          • TABLE 90: EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 141: EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • S1P Receptor Modulators
        • Overview
        • Revenue
          • TABLE 91: EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 142: EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Nucleotide Receptor Drugs
      • P2Y Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 92: EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 143: EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
  • SECRETIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Glucagon-like Peptide (GLP) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 93: EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 144: EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
      • Smoothened (SMO) Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 94: EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 145: EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • Parathyroid Hormone (PTH) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 95: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 146: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
  • METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS
    • Ion Receptor Drugs
      • Calcium-Sensing Receptor (CaSR) Agonists
        • Overview
        • Revenue
          • TABLE 96: EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 147: EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
  • MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    • CARDIOVASCULAR DRUGS
      • TABLE 97: EU MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 148: EU MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
      • Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 149: EU MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
      • Platelet Aggregation Inibitors
        • Overview
        • Revenue
          • FIGURE 150: EU MARKET FOR gpcr PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
      • Other Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 151: EU MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
  • CENTRAL NERVOUS SYSTEM (CNS) DRUGS
    • TABLE 98: EU MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 152: EU MARKET SHARE OF CNS DRUG COMPANIES, 2013 (%)
    • Anti-Psychotics
      • Overview
      • Revenue
        • FIGURE 153: EU MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • Anti-Parkinson's Drugs
      • Overview
      • Revenue
        • FIGURE 154: EU MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • Anti-Migraine Drugs
      • Overview
      • Revenue
        • FIGURE 155: EU MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 ($ MILLIONS)
    • Nootropics
      • Overview
      • Revenue
        • FIGURE 156: EU MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • Psychostimulants
      • Overview
      • Revenue
        • FIGURE 157: EU MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • Analgesics
      • Overview
      • Revenue
        • FIGURE 158: EU MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • Opioid Dependence Medications
      • Overview
      • Revenue
        • FIGURE 159: EU MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
  • RESPIRATORY DRUGS
    • TABLE 99: EU MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 160: EU MARKET SHARE OFGPCR RESPIRATORY DRUG COMPANIES, 2013
    • Bronchodilators and Anti-inflammatories
      • Overview
      • Revenue
        • FIGURE 161: EU MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • Anti-Allergics
      • Overview
      • Revenue
        • FIGURE 162: EU MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
  • IMMUNOLOGY DRUGS
    • TABLE 100: EU MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 163: EU MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 ($ MILLIONS)
    • Immunosuppressants
      • Overview
      • Revenue
        • FIGURE 164: EU MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Retrovirals
      • Overview
      • Revenue
        • FIGURE 165: EU MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
  • ENDOCRINOLOGY/METABOLIC DRUGS
    • TABLE 101: EU MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 166: EU MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • Anti-Diabetics
      • Overview
      • Revenue
        • FIGURE 167: EU MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • Infertility Treatments
      • Overview
      • Revenue
        • FIGURE 168: EU MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • Hormone Therapies
      • Overview
      • Revenue
        • FIGURE 169: EU MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
  • ONCOLOGY DRUGS
    • TABLE 102: EU MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 170: EU MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013
    • Anti-Neoplastic Agents
      • Overview
      • Revenue
        • FIGURE 171: EU MARKET FOR GPCR ANTI-NEOPLASTIC AGENTS, 2010-2018 ($ MILLIONS)
    • Anti-Emetics
      • Overview
      • Revenue
        • FIGURE 172: EU MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • Hematopoietic Stem Cell Mobilizers
      • Overview
      • Revenue
        • FIGURE 173: EU MARKET FOR GPCR HSCMS, 2010-2018 ($ MILLIONS)
  • GENITOURINARY DRUGS
    • TABLE 103: EU MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 174: EU MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)
    • Anti-Diuretics
      • Overview
      • Revenue
        • FIGURE 175: EU MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • Diuretics
      • Overview
      • Revenue
        • FIGURE 176: EU MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
  • OPHTHALMIC DRUGS
    • Anti-Glaucoma Drugs
      • Overview
      • Revenue
        • TABLE 104: EU MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 177: EU MARKET FOR GPCR ANTI-GLAUCOMA AGENTS, 2010-2018 ($ MILLIONS)
        • FIGURE 178: EU MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013

CHAPTER 8 - MARKETS IN JAPAN

  • MARKET ANALYSIS
    • TABLE 105: JAPAN MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 179: JAPAN MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
  • RHODOPSIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Angiotensin II Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 106: JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
          • FIGURE 180: JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
      • Opioid Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 107: JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 181: JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Chemokine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 108: JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 182: JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Somatostatin Receptor Agonists
        • Overview
        • Revenue
          • TABLE 109: JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 183: JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
      • Neurokinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 110: JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 184: JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Vasopressin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 111: JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 185: JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Endothelin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 112: JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 186: JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Biogenic Amine Receptor Drugs
      • Muscarinic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 113: JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 187: JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Adrenergic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 114: JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 188: JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Dopamine Receptor Drugs
        • Overview
        • Revenue
          • TABLE 115: JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 189: JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Histamine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 116: JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 190: JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Serotonin Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 117: JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 191: JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • FSH, LH AND GNRH Receptor Drugs
        • Overview
        • Revenue
          • TABLE 118: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 192: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Lipid and Phospholipid Receptor Drugs
      • Eicosanoid Receptor Drugs
        • Overview
        • Revenue
          • TABLE 119: JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 193: JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • S1P Receptor Modulators
        • Overview
        • Revenue
          • TABLE 120: JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 194: JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Nucleotide Receptor Drugs
      • P2Y Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 121: JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 195: JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
  • SECRETIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Glucagon-like peptide (GLP) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 122: JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 196: JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
      • Smoothened (SMO) Receptor Antagonists
    • Hormone Receptor Drugs
      • Parathyroid Hormone (PTH) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 123: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 197: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
  • METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS
    • Ion Receptor Drugs
      • Calcium-Sensing Receptor (CaSR) Agonists
        • Overview
        • Revenue
          • TABLE 124: JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 198: JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
  • JAPANESE MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    • CARDIOVASCULAR DRUGS
      • TABLE 125: JAPAN MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 199: JAPAN MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013
      • Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 200: JAPAN MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
      • Platelet Aggregation Inhibitors
        • Overview
        • Revenue
          • FIGURE 201: JAPAN MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
      • Other Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 202: JAPAN MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
  • CENTRAL NERVOUS SYSTEM (CNS) DRUGS
    • TABLE 126: JAPAN MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 203: JAPAN MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013
    • Anti-Psychotics
      • Overview
      • Revenue
        • FIGURE 204: JAPAN MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • Anti-Parkinson's Drugs
      • Overview
      • Revenue
        • FIGURE 205: JAPAN MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • Anti-Migraine Drugs
      • Overview
      • Revenue
        • FIGURE 206: JAPAN MARKET FOR GPCR ANTI-MIGRAINE, 2010-2018 ($ MILLIONS)
    • Nootropics
      • Overview
      • Revenue
        • FIGURE 207: JAPAN MARKET FOR GPCR NOOTROPICS, THROUGH 2018 ($ MILLIONS)
    • Psychostimulants
      • Overview
      • Revenue
        • FIGURE 208: JAPAN MARKET FOR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • Analgesics
      • Overview
      • Revenue
        • FIGURE 209: JAPAN MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • Opioid Dependence Medications
      • Overview
      • Revenue
        • FIGURE 210: JAPAN MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
  • RESPIRATORY DRUGS
    • TABLE 127: JAPAN MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 211: JAPAN MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013
    • Bronchodilators and Anti-Inflammatories
      • Overview
      • Revenue
        • FIGURE 212: JAPAN MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • Anti-Allergics
      • Overview
      • Revenue
        • FIGURE 213: JAPAN MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
  • IMMUNOLOGY DRUGS
    • TABLE 128: JAPAN MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 214: JAPAN MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013
    • Immunosuppressants
      • Overview
      • Revenue
        • FIGURE 215: JAPAN MARKET FOR IMMUNOSUPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Retrovirals
      • Overview
      • Revenue
        • FIGURE 216: JAPAN MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
  • ENDOCRINOLOGY/METABOLIC DRUGS
    • TABLE 129: JAPAN MARKET FOR GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 217: JAPAN MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • Anti-Diabetics
      • Overview
      • Revenue
        • FIGURE 218: JAPAN GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • Infertility Treatments
      • Overview
      • Revenue
        • FIGURE 219: JAPAN GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • Hormone Therapies
      • Overview
      • Revenue
        • FIGURE 220: JAPAN MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
  • ONCOLOGY DRUGS
    • TABLE 130: JAPAN MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 221: JAPAN MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013
    • Anti-Neoplastic Agents
      • Overview
      • Revenue
        • FIGURE 222: JAPAN MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • Anti-Emetics
      • Overview
      • Revenue
        • FIGURE 223: JAPAN MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
  • GENITOURINARY DRUGS
    • TABLE 131: JAPAN MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 224: JAPAN MARKET SHARE OFGPCR GENITOURINARY DRUG COMPANIES, 2013 ($ MILLIONS)
    • Anti-Diuretics
      • Overview
      • Revenue
        • FIGURE 225: JAPAN MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • Diuretics
      • Overvie
      • Revenue
        • FIGURE 226: JAPAN MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
  • OPHTHALMIC DRUGS
    • Anti-Glaucoma Drugs
      • Overview
      • Revenue
        • TABLE 132: JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 227: JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
        • FIGURE 228: JAPAN MARKET SHARE OF OPHTHALMIC DRUG COMPANIES, THROUGH 2018

CHAPTER 9 - MARKETS IN BRIC

  • MARKET ANALYSIS
    • TABLE 133: BRIC MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 229: BRIC MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
  • RHODOPSIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Angiotensin II Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 134: BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
          • FIGURE 230: BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
      • Bradykinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 135: BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 231: BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Opioid Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 136: BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 232: BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Chemokine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 137: BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 233: BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Somatostatin Receptor Agonists
        • Overview
        • Revenue
          • TABLE 138: BRIC MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 234: BRIC MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
      • Endothelin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 139: BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 235: BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Biogenic Amine Receptor Drugs
      • Muscarinic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 140: BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 236: BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Adrenergic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 141: BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 237: BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Dopamine Receptor Drugs
        • Overview
        • Revenue
          • TABLE 142: BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 238: BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Histamine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 143: BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 239: BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Serotonin Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 144: BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 240: BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • FSH, LH AND GNRH Receptor Drugs
        • Overview
        • Revenue
          • TABLE 145: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 241: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Lipid and Phospholipid Receptor Drugs
      • Eicosanoid Receptor Drugs
        • Overview
        • Revenue
          • TABLE 146 BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 242 BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • S1P Receptor Modulators
        • Overview
        • Revenue
          • TABLE 147: BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 243: BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, 2010-2018 ($ MILLIONS)
    • Nucleotide Receptor Drugs
      • P2Y Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 148: BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 244: BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
  • SECRETIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Glucagon-like Peptide (GLP) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 149: BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 245: BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • Parathyroid Hormone (PTH) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 150: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 246: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
  • METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS
    • Ion Receptor Drugs
      • Calcium-Sensing Receptor (CaSR) Agonists
        • Overview
        • Revenue
          • TABLE 151: BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 247: BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, 2010-2018 ($ MILLIONS)
  • MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    • CARDIOVASCULAR DRUGS
      • TABLE 152: BRIC MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 248: BRIC MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
      • Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 249: BRIC MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
      • Platelet Aggregation Inhibitors
        • Overview
        • Revenue
          • FIGURE 250: BRIC MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
      • Other Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 251: BRIC MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
  • CENTRAL NERVOUS SYSTEM (CNS) DRUGS
    • TABLE 153: BRIC MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 252: BRIC MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)
    • Anti-Psychotics
      • Overview
      • Revenue
        • FIGURE 253: BRIC MARKET FOR gpcr ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • Anti-Parkinson's Drugs
      • Overview
      • Revenue
        • FIGURE 254: BRIC MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • Anti-Migraine Drugs
      • Overview
      • Revenue
        • FIGURE 255: BRIC MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 ($ MILLIONS)
    • Nootropics
      • Overview
      • Revenue
        • FIGURE 256: BRIC MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • Psychostimulants
      • Overview
      • Revenue
        • FIGURE 257: BRIC MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • Analgesics
      • Overview
      • Revenue
        • FIGURE 258: BRIC MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • Opioid Dependence Medications
      • Overview
      • Revenue
        • FIGURE 259: BRIC MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
  • RESPIRATORY DRUGS
    • TABLE 154: BRIC MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 260: BRIC MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013
    • Bronchodilators and Anti-Inflammatories
      • Overview
      • Revenue
        • FIGURE 261: BRIC MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • Anti-Allergics
      • Overview
      • Revenue
      • FIGURE 262: BRIC MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
  • IMMUNOLOGY DRUGS
    • TABLE 155: BRIC MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 263: BRIC MARKET SHARE OFGPCR IMMUNOLOGY DRUG COMPANIES, 2013
    • Immunosuppressants
      • Overview
      • Revenue
        • FIGURE 264: BRIC MARKET OF GPCR IMMUNOSUPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Retrovirals
      • Overview
      • Revenue
        • FIGURE 265: BRIC MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
  • ENDOCRINOLOGY/METABOLIC DRUGS
    • TABLE 156: BRIC MARKET OF ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 266: BRIC MARKET SHARE OF ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, THROUGH 2018
    • Anti-Diabetics
      • Overview
      • Revenue
        • FIGURE 267: BRIC MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • Infertility Treatments
      • Overview
      • Revenue
        • FIGURE 268: BRIC MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • Hormone Therapies
      • Overview
      • Revenue
        • FIGURE 269: BRIC MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
  • ONCOLOGY DRUGS
    • TABLE 157: BRIC MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 270: BRIC MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013
    • Anti-Neoplastic Agents
      • Overview
      • Revenue
        • FIGURE 271: BRIC MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • Anti-Emetics
      • Overview
      • Revenue
        • FIGURE 272: BRIC MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
  • GENITOURINARY DRUGS
    • TABLE 158: BRIC MARKET FOR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 273: BRIC MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013
    • Anti-Diuretics
      • Overview
      • Revenue
        • FIGURE 274: BRIC MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLION`S)
  • OPHTHALMIC DRUGS
    • Anti-Glaucoma Drugs
      • Overview
      • Revenue
        • TABLE 159: BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 275: BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
        • FIGURE 276: BRIC MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013

CHAPTER 10 - MARKETS IN THE REST OF THE WORLD

  • MARKET ANALYSIS
    • TABLE 160: ROW MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 277: ROW MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
  • RHODOPSIN-LIKE RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Angiotensin II Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 161: ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
          • FIGURE 278: ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
      • Bradykinin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 162: ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 279: ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Opioid Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 163: ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 280: ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Chemokine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 164: ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 281: ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
      • Somatostatin Receptor Agonists
        • Overview
        • Revenue
          • TABLE 165: ROW MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 282: ROW MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
      • Endothelin Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 166: ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 283: ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • Biogenic Amine Receptor Drugs
      • Muscarinic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 167: ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 284: ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Adrenergic Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 168: ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 285: ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Dopamine Receptor Drugs
        • Overview
        • Revenue
          • TABLE 169: ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 286: ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Histamine Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 170: ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 287: ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • Serotonin Receptor Targeting Drugs
        • Overview
        • Revenue
          • TABLE 171: ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 288: ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • FSH, LH AND GNRH Receptor Drugs
        • Overview
        • Revenue
          • TABLE 172: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 289: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Lipid and Phospholipid Receptor Drugs
      • Eicosanoid Receptor Drugs
        • Overview
        • Revenue
          • TABLE 173: ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 290: ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
      • S1P Receptor Modulators
        • Overview
        • Revenue
          • TABLE 174: ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 291: ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • Nucleotide Receptor Drugs
      • P2Y Receptor Antagonists
        • Overview
        • Revenue
          • TABLE 175: ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 292: ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
  • SECRETIN RECEPTOR DRUGS
    • Peptide Receptor Drugs
      • Glucagon-like Peptide (GLP) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 176: ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 293: ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • Hormone Receptor Drugs
      • Parathyroid Hormone (PTH) Receptor Agonists
        • Overview
        • Revenue
          • TABLE 177: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
          • FIGURE 294: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
  • METABOTROPIC GLUTAMATE-LIKE RECEPTOR DRUGS
    • Ion Receptor Drugs
      • Calcium-Sensing Receptor (CaSR) Agonists
        • Overview
        • Revenue
          • TABLE 178: ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
          • FIGURE 295: ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
  • MARKET ANALYSIS BY THERAPEUTIC APPLICATION
    • CARDIOVASCULAR DRUGS
      • TABLE 179: ROW MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
      • FIGURE 296: ROW MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
      • Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 297: ROW MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
      • Platelet Aggregation Inhibitors
        • Overview
        • Revenue
          • FIGURE 298: ROW MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
      • Other Anti-Hypertensives
        • Overview
        • Revenue
          • FIGURE 299: ROW MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
  • CENTRAL NERVOUS SYSTEM (CNS) DRUGS
    • TABLE 180: ROW MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 300: ROW MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013
    • Anti-Psychotics
      • Overview
      • Revenue
        • FIGURE 301: ROW MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • Anti-Parkinson's Drugs
      • Overview
      • Revenue
        • FIGURE 302: ROW MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • Anti-Migraine Drugs
      • Overview
      • Revenue
        • FIGURE 303: ROW MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 ($ MILLIONS)
    • Nootropics
      • Overview
      • Revenue
        • FIGURE 304: ROW MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • Psychostimulants
      • Overview
      • Revenue
        • FIGURE 305: ROW MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • Analgesics
      • Overview
      • Revenue
        • FIGURE 306: ROW MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • Opioid Dependence Medications
      • Overview
      • Revenue
        • FIGURE 307: ROW MARKET FOR GPCR OPIOID DEPENDENCE, 2010-2018 ($ MILLIONS)
  • RESPIRATORY DRUGS
    • TABLE 181: ROW MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 308: ROW MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)
    • Bronchodilators and Anti-Inflammatories
      • Overview
      • Revenue
        • FIGURE 309: ROW MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • Anti-Allergics
      • Overview
      • Revenue
        • FIGURE 310: ROW MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
  • IMMUNOLOGY DRUGS
    • TABLE 182: ROW MARKET OF GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 311: ROW MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 ($ MILLIONS)
    • Immunosuppressants
      • Overview
      • Revenue
        • FIGURE 312: ROW MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 ($ MILLIONS)
    • Anti-Retrovirals
      • Overview
      • Revenue
        • FIGURE 313: ROW MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
  • ENDOCRINOLOGY/METABOLIC DRUGS
    • TABLE 183: ROW MARKET OF GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 314: ROW MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • Anti-Diabetics
      • Overview
      • Revenue
        • FIGURE 315: ROW MARKET FOT GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • Infertility Treatments
      • Overview
      • Revenue
        • FIGURE 316: ROW MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • Hormone Therapies
      • Overview
      • Revenue
        • FIGURE 317: ROW MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
  • ONCOLOGY DRUGS
    • TABLE 184: ROW MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 318: ROW MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 (%)
    • Anti-Neoplastic Agents
      • Overview
      • Revenue
        • FIGURE 319: ROW MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • Anti-Emetics
      • Overview
      • Revenue
        • FIGURE 320: ROW MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • Hematopoietic Stem Cell Mobilizers
      • Overview
      • Revenue
        • FIGURE 321: ROW MARKET FOR HSC MOBILIZERS, 2010-2018 ($ MILLIONS)
  • GENITOURINARY DRUGS
    • TABLE 185: ROW MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 322: ROW MARKET SHARE OF GENITOURINARY DRUG COMPANIES, THROUGH 2018 (%)
    • Anti-Diuretics
      • Overview
      • Revenue
        • FIGURE 323: ROW MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
  • OPHTHALMIC DRUGS
    • Anti-Glaucoma Drugs
      • Overview
      • Revenue
        • TABLE 186: ROW MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
        • FIGURE 324: ROW MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
        • FIGURE 325: ROW MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)

CHAPTER 11 - COMPANY PROFILES

  • ABBOTT LABORATORIES
  • ABBVIE INC.
  • ACTELION PHARMACEUTICALS LTD.
  • ADDEX THERAPEUTICS
  • ALCON INC.
  • ALKERMES PLC.
  • ALLERGAN INC.
  • AMGEN INC.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC.
  • BOEHRINGER INGELHEIM GMBH
  • BRISTOL-MYERS SQUIBB
  • CHEMOCENTRYX INC.
  • DAIICHI SANKYO CO., LTD.
  • DAINIPPON SUMITOMO PHARMA CO., LTD.
  • ELI LILLY AND CO.
  • EMD SERONO INC.
  • ENDO HEALTH SOLUTIONS INC.
  • F. HOFFMANN-LA ROCHE LTD.
  • FOREST LABORATORIES INC.
  • GILEAD SCIENCES INC.
  • GLAXOSMITHKLINE PLC.
  • HELSINN HEALTHCARE S.A.
  • HEPTARES THERAPEUTICS
  • IPSEN S.A.
  • JOHNSON & JOHNSON
  • KYOWA HAKKO KIRIN CO., LTD.
  • LUNDBECK INC.
  • MERCK & CO. INC.
  • MITSUBISHI TANABE PHARMA CORP.
  • NEKTAR THERAPEUTICS
  • NOVARTIS INTERNATIONAL AG
  • NOVO NORDISK A.S.
  • NPS PHARMACEUTICALS
  • ONO PHARMACEUTICAL CO., LTD.
  • OREXO AB
  • OTSUKA HOLDINGS CO., LTD.
  • PFIZER INC.
  • PURDUE PHARMA L.P.
  • RECKITT BENCKISER PHARMACEUTICALS INC.
  • RETROPHIN INC.
  • SANOFI S.A.
  • SANTEN PHARMACEUTICAL CO., LTD.
  • SHIRE PLC.
  • TAKEDA PHARMACEUTICAL CO., LTD
  • TREVENA INC.
  • UCB S.A.
  • UNITED THERAPEUTICS CORP.
  • VALEANT PHARMACEUTICALS INTERNATIONAL INC.
  • VIIV HEALTHCARE

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: CLASSIFICATION OF THE GPCR-TARGETING DRUGS
    • TABLE 2: FDA-APPROVED GPCR TARGETING DRUGS, 2010-2014
    • TABLE 3: POSITIVE OPINION GRANTED BY THE EMA TO GPCR TARGETING DRUGS, 2012-2014
    • TABLE 4: BOX WARNINGS ENFORCED BY THE FDA FOR THE USE OF SELECTED GPCR-TARGETING DRUGS
    • TABLE 5: GLOBAL MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 6: ARB'S IN DEVELOPMENT, BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 7: GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
    • TABLE 8: GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 9: OPIOIDS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 10: GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 11: CHEMOKINE RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 12: GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 13: SOMATOSTATIN RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 14: GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 15: GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 16: GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 17: GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 18: GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 19: GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 20: GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 21: GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 22: SEROTONIN RECEPTOR ANTAGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 23: GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 24: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 25: EICOSANOID RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 26: GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 27: S1P RECEPTOR MODULATORS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 28: GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 29: GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 30: GLOBAL MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 31: GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT: BY COMPANY, CLINICAL PHASE AND EXPECTED YEAR OF ARRIVAL TO THE MARKET
    • TABLE 32: GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 35: GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 36: GLOBAL MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 37: GLOBAL MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 38: GLOBAL MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 39: GLOBAL MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 40: GLOBAL MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 41: GLOBAL MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 42: GLOBAL MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 43: GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 44: U.S. MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 45: U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
    • TABLE 46: U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 47: U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 48: U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 49: U.S. MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 50: U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 51: U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 52: U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 53: U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 54: U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 55: U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 56: U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 57: U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 58: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 59: U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 60: U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 61: U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 62: U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 63: U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 64: U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 65: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 66: U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 67: U.S. MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 68: U.S. MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 69: U.S. MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 70: U.S. MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 71: U.S. MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 72: U.S. MARKET FOR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 73: U.S. MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 74: U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 75: EU MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 76: EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
    • TABLE 77: EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 78: EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 79: EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 80: EU MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 81: EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 82: EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 83: EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 84: EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 85: EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 86: EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 87: EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 88: EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 89: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 90: EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 91: EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 92: EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 93: EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 94: EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 95: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 96: EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 97: EU MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 98: EU MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 99: EU MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 100: EU MARKET FOR GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 101: EU MARKET FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 102: EU MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 103: EU MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 104: EU MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 105: JAPAN MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 106: JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
    • TABLE 107: JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 108: JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 109: JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 110: JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 111: JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 112: JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 113: JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 114: JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 115: JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 116: JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 117: JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 118: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 119: JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 120: JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 121: JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 122: JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 123: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 124: JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 125: JAPAN MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 126: JAPAN MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 127: JAPAN MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 128: JAPAN MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 129: JAPAN MARKET FOR GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 130: JAPAN MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 131: JAPAN MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 132: JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 133: BRIC MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 134: BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
    • TABLE 135: BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 136: BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 137: BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 138: BRIC MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 139: BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 140: BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 141: BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 142: BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 143: BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 144: BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 145: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 146: BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 147: BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, THROUGH 2018 ($ MILLIONS)
    • TABLE 148: BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 149: BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 150: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 151: BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, THROUGH 2018 ($ MILLIONS)
    • TABLE 152: BRIC MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 153: BRIC MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 154: BRIC MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 155: BRIC MARKET FOR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 156: BRIC MARKET OF ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 157: BRIC MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 158: BRIC MARKET FOR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 159: BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 160: ROW MARKET FOR GPCR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 161: ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), THROUGH 2018 ($ MILLIONS)
    • TABLE 162: ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 163: ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 164: ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 165: ROW MARKET FOR SOMATOSTATIN ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 166: ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 167: ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 168: ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 169: ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 170: ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 171: ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 172: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 173: ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 174: ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 175: ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 176: ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, THROUGH 2018 ($ MILLIONS)
    • TABLE 177: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 178: ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, THROUGH 2018 ($ MILLIONS)
    • TABLE 179: ROW MARKET FOR GPCR CARDIOVASCULAR DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 180: ROW MARKET FOR GPCR CNS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 181: ROW MARKET FOR GPCR RESPIRATORY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 182: ROW MARKET OF GPCR IMMUNOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 183: ROW MARKET OF GPCR ENDOCRINOLOGY/METABOLICS DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 184: ROW MARKET FOR GPCR ONCOLOGY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 185: ROW MARKET FOR GPCR GENITOURINARY DRUGS, THROUGH 2018 ($ MILLIONS)
    • TABLE 186: ROW MARKET FOR GPCR OPHTHALMIC DRUGS, THROUGH 2018 ($ MILLIONS)

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 2: GLOBAL MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
    • FIGURE 3: GLOBAL MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 4: GLOBAL MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 5: GLOBAL MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 6: GLOBAL MARKET FOR SOMATOSTATIN RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 7: GLOBAL MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 8: GLOBAL MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 9: GLOBAL MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 10: GLOBAL MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 11: GLOBAL MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 12: GLOBAL MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 13: GLOBAL MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 14: GLOBAL MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 15: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 16: GLOBAL MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 17: GLOBAL MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 18: GLOBAL MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 19: GLOBAL MARKET FOR AMYLIN RECEPTOR AGONIST, 2010-2018 ($ MILLIONS)
    • FIGURE 20: GLOBAL MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 21: GLOBAL MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 22: GLOBAL MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 23: GLOBAL MARKET FOR CALCIUM-SENSING RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 24: GLOBAL MARKET SHARE FOR GPCR CARDIOVASCULAR DRUGS, 2013 (%)
    • FIGURE 25: GLOBAL MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
    • FIGURE 26: REGIONAL MARKETS FOR GPCR CARDIOVASCULAR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 27: GLOBAL MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 28: GLOBAL MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
    • FIGURE 29: GLOBAL MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 30: GLOBAL MARKET SHARE FOR GPCR CNS DRUGS, 2013 (%)
    • FIGURE 31: GLOBAL MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)
    • FIGURE 32: REGIONAL MARKETS FOR GPCR CNS DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 33: GLOBAL MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 34: GLOBAL MARKET FOR GPCR ANTI-DEPPRESSANT DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 35: GLOBAL MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 36: GLOBAL MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 37: GLOBAL MARKET FOR GPCR NOOTROPIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 38: GLOBAL MARKET FOR GPCR PSYCHOSTIMULANT DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 39: GLOBAL MARKET FOR GPCR ANALGESIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 40: GLOBAL MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
    • FIGURE 41: GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUGS, 2013 (%)
    • FIGURE 42: GLOBAL MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)
    • FIGURE 43: REGIONAL MARKETS FOR GPCR RESPIRATORY DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 44: GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 ($ MILLIONS)
    • FIGURE 45: GLOBAL MARKET FOR GPCR BRONCHODILATORS, 2010-2018 ($ MILLIONS)
    • FIGURE 46: GLOBAL MARKET SHARE FOR GPCR IMMUNOLOGY DRUGS, 2013
    • FIGURE 47: GLOBAL MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)
    • FIGURE 48: REGIONAL MARKETS FOR THE GPCR IMMUNOLOGY DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 49: GLOBAL MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010--2018 ($ MILLIONS)
    • FIGURE 50: GLOBAL MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
    • FIGURE 51: GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2013 (%)
    • FIGURE 52: GLOBAL MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLIC DRUG COMPANIES, 2013 (%)
    • FIGURE 53: REGIONAL MARKETS FOR GPCR ENDOCRINOLOGY/METABOLIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 54: GLOBAL MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 55: GLOBAL MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 56: GLOBAL MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
    • FIGURE 57: GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUGS, 2013
    • FIGURE 58: GLOBAL MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 ($ MILLIONS)
    • FIGURE 59: REGIONAL MARKET FOR GPCR ONCOLOGY DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 60: GLOBAL MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 61: GLOBAL MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 62: GLOBAL MARKET FOR GPCR HEMATOPOIETIC STEM CELL MOBILIZERS, 2010-2018 ($ MILLIONS)
    • FIGURE 63: GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUGS, 2013 (%)
    • FIGURE 64: GLOBAL MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)
    • FIGURE 65: REGIONAL MARKET FOR GPCR GENITOURINARY DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 66: GLOBAL MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 67: GLOBAL MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 68: GLOBAL MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)
    • FIGURE 69: REGIONAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 70: GLOBAL MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 71: U.S. MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 72: U.S. MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
    • FIGURE 73: U.S. MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 74: U.S. MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 75: U.S. MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 76: U.S. MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 77: U.S. MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 78: U.S. MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 79: U.S. MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 80: U.S. MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 81: U.S. MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 82: U.S. MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 83: U.S. MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 84: U.S. MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 85: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 86: U.S. MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 87: U.S. MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 88: U.S. MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 89: U.S. MARKET FOR MARKET FOR AMYLIN RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 90: U.S. MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 91: U.S. MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 92: U.S. MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 93: U.S. MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 94: U.S. MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
    • FIGURE 95: U.S. MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 96: U.S. MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
    • FIGURE 97: U.S. MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 98: U.S. MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013
    • FIGURE 99: U.S. MARKET FOR GPCR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 100: U.S. MARKET FOR GPCR ANTI-DEPRESSANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 101: U.S. MARKET FOR GPCR ANTI-PARKINSON'S DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 102: U.S. MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 103: U.S. MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • FIGURE 104: U.S. MARKET FOR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 105: U.S. MARKET FOR ANALGESICS, 2010-2018 ($ MILLIONS)
    • FIGURE 106: U.S. MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
    • FIGURE 107: U.S. MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)
    • FIGURE 108: U.S. MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • FIGURE 109: U.S. MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
    • FIGURE 110: U.S. MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 (%)
    • FIGURE 111: U.S. MARKET FOR GPCR IMMUNOSUPRESSANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 112: U.S. MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
    • FIGURE 113: U.S. MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • FIGURE 114: U.S. MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 115: U.S. MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 116: U.S. MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
    • FIGURE 117: U.S. MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, THROUGH 2018 (%)
    • FIGURE 118: U.S. MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 119: U.S. MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 120: U.S. MARKET FOR GPCR HSCMS, 2010-2018 ($ MILLIONS)
    • FIGURE 121: U.S. MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)
    • FIGURE 122: U.S. MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 123: U.S. MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 124: U.S. MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 125: U.S. MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)
    • FIGURE 126: EU MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 127: EU MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
    • FIGURE 128: EU MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 129: EU MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 130: EU MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 131: EU MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 132: EU MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 133: EU MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 134: EU MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 135: EU MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 136: EU MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 137: EU MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 138: EU MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 139: EU MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 140: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 141: EU MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 142: EU MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 143: EU MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 144: EU MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 145: EU MARKET FOR SMOOTHENED RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 146: EU MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 147: EU MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 148: EU MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
    • FIGURE 149: EU MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 150: EU MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
    • FIGURE 151: EU MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 152: EU MARKET SHARE OF CNS DRUG COMPANIES, 2013 (%)
    • FIGURE 153: EU MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 154: EU MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • FIGURE 155: EU MARKET FOR GPCR ANTI-MIGRAINE DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 156: EU MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • FIGURE 157: EU MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 158: EU MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • FIGURE 159: EU MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
    • FIGURE 160: EU MARKET SHARE OFGPCR RESPIRATORY DRUG COMPANIES, 2013
    • FIGURE 161: EU MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • FIGURE 162: EU MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
    • FIGURE 163: EU MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 ($ MILLIONS)
    • FIGURE 164: EU MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 165: EU MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
    • FIGURE 166: EU MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • FIGURE 167: EU MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 168: EU MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 169: EU MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
    • FIGURE 170: EU MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013
    • FIGURE 171: EU MARKET FOR GPCR ANTI-NEOPLASTIC AGENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 172: EU MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 173: EU MARKET FOR GPCR HSCMS, 2010-2018 ($ MILLIONS)
    • FIGURE 174: EU MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013 (%)
    • FIGURE 175: EU MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 176: EU MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 177: EU MARKET FOR GPCR ANTI-GLAUCOMA AGENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 178: EU MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013
    • FIGURE 179: JAPAN MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 180: JAPAN MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
    • FIGURE 181: JAPAN MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 182: JAPAN MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 183: JAPAN MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 184: JAPAN MARKET FOR NEUROKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 185: JAPAN MARKET FOR VASOPRESSIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 186: JAPAN MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 187: JAPAN MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 188: JAPAN MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 189: JAPAN MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 190: JAPAN MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 191: JAPAN MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 192: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 193: JAPAN MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 194: JAPAN MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 195: JAPAN MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 196: JAPAN MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 197: JAPAN MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 198: JAPAN MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 199: JAPAN MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013
    • FIGURE 200: JAPAN MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 201: JAPAN MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
    • FIGURE 202: JAPAN MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 203: JAPAN MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013
    • FIGURE 204: JAPAN MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 205: JAPAN MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • FIGURE 206: JAPAN MARKET FOR GPCR ANTI-MIGRAINE, 2010-2018 ($ MILLIONS)
    • FIGURE 207: JAPAN MARKET FOR GPCR NOOTROPICS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 208: JAPAN MARKET FOR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 209: JAPAN MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • FIGURE 210: JAPAN MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
    • FIGURE 211: JAPAN MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013
    • FIGURE 212: JAPAN MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • FIGURE 213: JAPAN MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
    • FIGURE 214: JAPAN MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013
    • FIGURE 215: JAPAN MARKET FOR IMMUNOSUPRESSANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 216: JAPAN MARKET FOR GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
    • FIGURE 217: JAPAN MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • FIGURE 218: JAPAN GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 219: JAPAN GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 220: JAPAN MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
    • FIGURE 221: JAPAN MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013
    • FIGURE 222: JAPAN MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 223: JAPAN MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 224: JAPAN MARKET SHARE OFGPCR GENITOURINARY DRUG COMPANIES, 2013 ($ MILLIONS)
    • FIGURE 225: JAPAN MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 226: JAPAN MARKET FOR GPCR DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 227: JAPAN MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 228: JAPAN MARKET SHARE OF OPHTHALMIC DRUG COMPANIES, THROUGH 2018
    • FIGURE 229: BRIC MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 230: BRIC MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
    • FIGURE 231: BRIC MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 232: BRIC MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 233: BRIC MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 234: BRIC MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 235: BRIC MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 236: BRIC MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 237: BRIC MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 238: BRIC MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 239: BRIC MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 240: BRIC MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 241: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 242: BRIC MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 243: BRIC MARKET FOR SPHINGOPHOSPHATE RECEPTOR MODULATORS, 2010-2018 ($ MILLIONS)
    • FIGURE 244: BRIC MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 245: BRIC MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 246: BRIC MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 247: BRIC MARKET FOR CALCIUM-SENSING RECEPTOR MODULATORS, 2010-2018 ($ MILLIONS)
    • FIGURE 248: BRIC MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
    • FIGURE 249: BRIC MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 250: BRIC MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
    • FIGURE 251: BRIC MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 252: BRIC MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013 (%)
    • FIGURE 253: BRIC MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 254: BRIC MARKET FOR GPCR ANTI-PARKINSON'S, 2010--2018 ($ MILLIONS)
    • FIGURE 255: BRIC MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 ($ MILLIONS)
    • FIGURE 256: BRIC MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • FIGURE 257: BRIC MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 258: BRIC MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • FIGURE 259: BRIC MARKET FOR GPCR OPIOID DEPENDENCE MEDICATIONS, 2010-2018 ($ MILLIONS)
    • FIGURE 260: BRIC MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013
    • FIGURE 261: BRIC MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • FIGURE 262: BRIC MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
    • FIGURE 263: BRIC MARKET SHARE OFGPCR IMMUNOLOGY DRUG COMPANIES, 2013
    • FIGURE 264: BRIC MARKET OF GPCR IMMUNOSUPRESSANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 265: BRIC MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
    • FIGURE 266: BRIC MARKET SHARE OF ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, THROUGH 2018
    • FIGURE 267: BRIC MARKET FOR GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 268: BRIC MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 269: BRIC MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
    • FIGURE 270: BRIC MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013
    • FIGURE 271: BRIC MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 272: BRIC MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 273: BRIC MARKET SHARE OF GPCR GENITOURINARY DRUG COMPANIES, 2013
    • FIGURE 274: BRIC MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLION`S)
    • FIGURE 275: BRIC MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 276: BRIC MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013
    • FIGURE 277: ROW MARKET FOR GPCR DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 278: ROW MARKET FOR ANGIOTENSIN RECEPTOR BLOCKERS (ARBS), 2010-2018 ($ MILLIONS)
    • FIGURE 279: ROW MARKET FOR BRADYKININ RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 280: ROW MARKET FOR OPIOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 281: ROW MARKET FOR CHEMOKINE RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 282: ROW MARKET FOR SOMATOSTATIN ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 283: ROW MARKET FOR ENDOTHELIN RECEPTOR ANTAGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 284: ROW MARKET FOR MUSCARINIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 285: ROW MARKET FOR ADRENERGIC RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 286: ROW MARKET FOR DOPAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 287: ROW MARKET FOR HISTAMINE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 288: ROW MARKET FOR SEROTONIN RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 289: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 290: ROW MARKET FOR EICOSANOID RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 291: ROW MARKET FOR SPHINGOPHOSPHATE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 292: ROW MARKET FOR P2Y RECEPTOR ANTAGONIST DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 293: ROW MARKET FOR GLUCAGON-LIKE PEPTIDE RECEPTOR AGONISTS, 2010-2018 ($ MILLIONS)
    • FIGURE 294: ROW MARKET FOR HORMONE RECEPTOR TARGETING DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 295: ROW MARKET FOR CALCIUM-SENSING RECEPTOR ANALOGUES, 2010-2018 ($ MILLIONS)
    • FIGURE 296: ROW MARKET SHARE OF GPCR CARDIOVASCULAR DRUG COMPANIES, 2013 (%)
    • FIGURE 297: ROW MARKET FOR GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 298: ROW MARKET FOR GPCR PLATELET AGGREGATION INHIBITORS, 2010-2018 ($ MILLIONS)
    • FIGURE 299: ROW MARKET FOR OTHER GPCR ANTI-HYPERTENSIVES, 2010-2018 ($ MILLIONS)
    • FIGURE 300: ROW MARKET SHARE OF GPCR CNS DRUG COMPANIES, 2013
    • FIGURE 301: ROW MARKET FOR GPCR ANTI-PSYCHOTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 302: ROW MARKET FOR GPCR ANTI-PARKINSON'S, 2010-2018 ($ MILLIONS)
    • FIGURE 303: ROW MARKET FOR GPCR ANTI-MIGRAINES, 2010-2018 ($ MILLIONS)
    • FIGURE 304: ROW MARKET FOR GPCR NOOTROPICS, 2010-2018 ($ MILLIONS)
    • FIGURE 305: ROW MARKET FOR GPCR PSYCHOSTIMULANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 306: ROW MARKET FOR GPCR ANALGESICS, 2010-2018 ($ MILLIONS)
    • FIGURE 307: ROW MARKET FOR GPCR OPIOID DEPENDENCE, 2010-2018 ($ MILLIONS)
    • FIGURE 308: ROW MARKET SHARE OF GPCR RESPIRATORY DRUG COMPANIES, 2013 (%)
    • FIGURE 309: ROW MARKET FOR GPCR BRONCHODILATORS AND ANTI-INFLAMMATORIES, 2010-2018 ($ MILLIONS)
    • FIGURE 310: ROW MARKET FOR GPCR ANTI-ALLERGICS, 2010-2018 ($ MILLIONS)
    • FIGURE 311: ROW MARKET SHARE OF GPCR IMMUNOLOGY DRUG COMPANIES, 2013 ($ MILLIONS)
    • FIGURE 312: ROW MARKET FOR GPCR IMMUNOSUPPRESSANTS, 2010-2018 ($ MILLIONS)
    • FIGURE 313: ROW MARKET OF GPCR ANTI-RETROVIRALS, 2010-2018 ($ MILLIONS)
    • FIGURE 314: ROW MARKET SHARE OF GPCR ENDOCRINOLOGY/METABOLICS DRUG COMPANIES, 2013
    • FIGURE 315: ROW MARKET FOT GPCR ANTI-DIABETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 316: ROW MARKET FOR GPCR INFERTILITY TREATMENTS, 2010-2018 ($ MILLIONS)
    • FIGURE 317: ROW MARKET FOR GPCR HORMONE THERAPIES, 2010-2018 ($ MILLIONS)
    • FIGURE 318: ROW MARKET SHARE OF GPCR ONCOLOGY DRUG COMPANIES, 2013 (%)
    • FIGURE 319: ROW MARKET FOR GPCR ANTI-NEOPLASTICS, 2010-2018 ($ MILLIONS)
    • FIGURE 320: ROW MARKET FOR GPCR ANTI-EMETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 321: ROW MARKET FOR HSC MOBILIZERS, 2010-2018 ($ MILLIONS)
    • FIGURE 322: ROW MARKET SHARE OF GENITOURINARY DRUG COMPANIES, THROUGH 2018 (%)
    • FIGURE 323: ROW MARKET FOR GPCR ANTI-DIURETICS, 2010-2018 ($ MILLIONS)
    • FIGURE 324: ROW MARKET FOR GPCR OPHTHALMIC DRUGS, 2010-2018 ($ MILLIONS)
    • FIGURE 325: ROW MARKET SHARE OF GPCR OPHTHALMIC DRUG COMPANIES, 2013 (%)
Back to Top